Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches

被引:24
作者
McMullin, Tami S.
Hanneman, William H.
Cranmer, Brian K.
Tessari, John D.
Andersen, Melvin E.
机构
[1] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA
[2] CIIT Ctr Hlth Res, Ctr Hlth Res, Res Triangle Pk, NC 27709 USA
关键词
PBPK modeling; atrazine; DACT;
D O I
10.1016/j.tox.2007.05.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atrazine (ATRA) is metabolized by cytochrome P450s to the chlorinated metabolites, 2-chloro-4-ethylamino-6-amino-1,3,5triazine(gTHYL),2-chloro-4-amino-6-is,opropylamino-1, 3,5-triazine (ISO), and diaminochlorotriazine (DACT). Here,we develop a set of physiologically based pharmacokinetic (PBPK) models that describe the influence of oral absorption and oxidative metabolism on the blood time course curves of individual chlorotriazines (Cl-TRIs) in rat after oral dosing of ATRA. These models first incorporated in vitro metabolic parameters to describe time course plasma concentrations of DACT, ETHYL, and ISO after dosing with each compound. Parameters from each individual model were linked together into a final composite model in order to describe, the time course of all 4 CI-TRIs after ATRA dosing. Oral administration of ISO, ETHYL and ATRA produced double peaks of the compounds in plasma time courses that were described by multiple absorption phases from gut. An adequate description of the uptake and bioavailability of absorbed ATRA also required inclusion of additional oxidative metabolic clearance of ATRA to the mono-dealkylated metabolites occurring in GI a tract compartment. These complex processes regulating tissue dosimetry of atrazine and its chlorinated metabolites likely reflect limited compound solubility in the gut from dosing with an emulsion, and sequential absorption and metabolism along the GI tract at these high oral doses. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 33 条
[1]   METABOLISM OF ATRAZINE AND 2-HYDROXYATRAZINE BY RAT [J].
BAKKE, JE ;
PRICE, CE ;
LARSON, JD .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 1972, 20 (03) :602-&
[2]   Physiological parameter values for physiologically based pharmacokinetic models [J].
Brown, RP ;
Delp, MD ;
Lindstedt, SL ;
Rhomberg, LR ;
Beliles, RP .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1997, 13 (04) :407-484
[3]   Quantitative identification of atrazine and its chlorinated metabolites in plasma [J].
Brzezicki, JM ;
Andersen, ME ;
Cranmer, BK ;
Tessari, JD .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2003, 27 (08) :569-573
[4]   Intestinal metabolism of PAR in vitro demonstration and study of its impact on PAH transfer through the intestinal epithelium [J].
Cavret, S ;
Feidt, C .
ENVIRONMENTAL RESEARCH, 2005, 98 (01) :22-32
[5]   Atrazine disrupts the hypothalamic control of pituitary-ovarian function [J].
Cooper, RL ;
Stoker, TE ;
Tyrey, L ;
Goldman, JM ;
McElroy, WK .
TOXICOLOGICAL SCIENCES, 2000, 53 (02) :297-307
[6]  
de Kanter R, 2002, CURR DRUG METAB, V3, P39
[7]   Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation [J].
Doherty, MM ;
Pang, KS .
PHARMACEUTICAL RESEARCH, 2000, 17 (03) :291-298
[8]   Identification of a novel hemoglobin adduct in Sprague Dawley rats exposed to atrazine [J].
Dooley, Greg P. ;
Prenni, Jessica E. ;
Prentiss, Pilar L. ;
Cranmer, Brian K. ;
Andersen, Melvin E. ;
Tessari, John D. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (05) :692-700
[9]  
ELDRIDGE JC, 2001, TOXICOLOGIST, V10, P200
[10]  
Gallo James M., 1993, Journal of Pharmacokinetics and Biopharmaceutics, V21, P551, DOI 10.1007/BF01059114